Tecvayli and Darzalex combination delivers in RRMM

US healthcare giant Johnson & Johnson (NYSE: JNJ) has announced new data from the investigational Phase III MajesTEC-3 study showing the potential of Tecvayli (teclistamab) plus Darzalex subcutaneous (daratumumab SC) formulation as early as second line for patients with relapsed/refractory multiple myeloma (RRMM).

Results show an 83.4% reduction in the risk of disease progression or death compared to standard regimens at nearly three years follow-up. More than 90% of patients who were progression-free at six months remained progression-free at three years.

The study evaluated the efficacy and safety of the investigational immunotherapy combination of teclistamab plus daratumumab SC versus daratumumab SC and dexamethasone with either pomalidomide or bortezomib in patients with RRMM who have received one to three prior lines of therapy.